We currently do not have sufficient information about the CEO.
Key information
Chei-Hsiang Chen
Chief executive officer
n/a
Total compensation
CEO salary percentage
n/a
CEO tenure
4.3yrs
CEO ownership
n/a
Management average tenure
6.2yrs
Board average tenure
4.3yrs
Recent management updates
Recent updates
CEO
Chei-Hsiang Chen
4.3yrs
Tenure
Dr. Chei-Hsiang Chen, Ph.D. has been President of UBI Pharma Inc. since January 2020 and has been its Chairperson since December 2019. He serves as General Manager at UBI Pharma Inc. Dr. Chen serves as the...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Chei-Hsiang Chen
Chairperson
4.3yrs
no data
no data
Meng Han Xu
Manager of the Finance Department
8.1yrs
no data
no data
Roger Kuo
Chief Operating Officer
10.3yrs
no data
no data
Jia Hong
Manager of Accounting Department
no data
no data
no data
Vivien Fan
Executive VP
4.3yrs
no data
no data
Yan Ning Guo
COO of Pharmaceutical Business Center & Director
no data
no data
no data
6.2yrs
Average Tenure
Experienced Management: 6562's management team is seasoned and experienced (6.2 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Chei-Hsiang Chen
Chairperson
4.4yrs
no data
no data
Vivien Fan
Executive VP
4.3yrs
no data
no data
Yan Ning Guo
COO of Pharmaceutical Business Center & Director
no data
no data
no data
Yau-Huei Wei
Independent Director
4.3yrs
no data
no data
Shijia Lin
Director
no data
no data
no data
4.3yrs
Average Tenure
Experienced Board: 6562's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/05/12 07:37
End of Day Share Price
2024/05/10 00:00
Earnings
2023/12/31
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UBI Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.